News Archive

June 2016

• Press Release Jun 28, 2016

  Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor

  Agreement is the latest in a series of acquisitions and strategic collaborations that have bolstered Novartis' deep and diverse immuno-oncology pipeline Collaboration will co-develop Xencor's…
• Press Release Jun 22, 2016

  Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology

  Findings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors) [1]   Cardiology experts…
• Press Release Jun 15, 2016

  Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment

  Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates…
• Press Release Jun 15, 2016

  Novartis erweitert Partnerschaft mit Medicines for Malaria Venture zur Entwicklung von Malariamedikamenten der nächsten Generation

  Novartis wird die Entwicklung des Malariapräparats KAF156 mit wissenschaftlicher und finanzieller Unterstützung von Medicines for Malaria Venture in Zusammenarbeit mit der Bill & Melinda Gates…
• Press Release Jun 15, 2016

  Novartis étend son partenariat avec Medicines for Malaria Venture pour développer la prochaine génération de traitement antipaludéen

  Novartis dirigera le développement de la molécule antipaludique KAF156 avec le soutien scientifique et financier de Medicines for Malaria Venture et en collaboration avec la Fondation Bill &…
• Press Release Jun 10, 2016

  Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder

  EXTEND study provides long-term safety data for Revolade that are consistent with the findings from the pivotal Phase III RAISE study[1,2] Immune thrombocytopenia (ITP) is a rare and potentially…
• Press Release Jun 10, 2016

  Novartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)

  Three times as many patients with inadequately controlled PV without enlarged spleen had hematocrit control without phlebotomy on Jakavi® (ruxolitinib) vs BAT[1]  RESPONSE-2 complements data…
• Press Release Jun 09, 2016

  New data demonstrates Sandoz' etanercept and rituximab biosimilar candidates bioequivalent to originator products

  Sandoz' biosimilar etanercept candidate shows pharmacokinetic (PK) bioequivalence with no clinically meaningful differences in safety, tolerability and immunogenicity to the originator.[1] …
• Press Release Jun 08, 2016

  Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention

  Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment  Migraine is a leading cause of disability,…
• Press Release Jun 08, 2016

  Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016

  Up to 80% of ankylosing spondylitis and 84% of psoriatic arthritis patients treated with Cosentyx® at two years had no radiographic progression in the spine or joints, respectively[1],[2] …
• Press Release Jun 06, 2016

  Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma

  Study is longest Ph III survival follow-up to date of BRAF V600E/K mutation-positive melanoma patients who received a targeted combination therapy  Latest data show an estimated 44% of…
• Press Release Jun 06, 2016

  Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer

  The median Duration of Response for BRAF V600E-mutant NSCLC patients treated with Tafinlar® + Mekinist® combination therapy was 9 months   Efficacy analyses also presented for INC280 (…